Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic.

Ramurthy S, Taft BR, Aversa RJ, Barsanti PA, Burger MT, Lou Y, Nishiguchi GA, Rico A, Setti L, Smith A, Subramanian S, Tamez V, Tanner H, Wan L, Hu C, Appleton BA, Mamo M, Tandeske L, Tellew JE, Huang S, Yue Q, Chaudhary A, Tian H, Iyer R, Hassan AQ, Mathews Griner LA, La Bonte LR, Cooke VG, Van Abbema A, Merritt H, Gampa K, Feng F, Yuan J, Mishina Y, Wang Y, Haling JR, Vaziri S, Hekmat-Nejad M, Polyakov V, Zang R, Sethuraman V, Amiri P, Singh M, Sellers WR, Lees E, Shao W, Dillon MP, Stuart DD.

J Med Chem. 2019 May 16. doi: 10.1021/acs.jmedchem.9b00161. [Epub ahead of print]

PMID:
31059256
2.

Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma.

Leung GP, Feng T, Sigoillot FD, Geyer FC, Shirley MD, Ruddy DA, Rakiec DP, Freeman AK, Engelman JA, Jaskelioff M, Stuart DD.

Mol Cancer Res. 2019 Jan;17(1):199-211. doi: 10.1158/1541-7786.MCR-18-0327. Epub 2018 Sep 10.

PMID:
30201825
3.

Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.

Shao W, Mishina YM, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner LA, Nishiguchi G, Rico A, Tellew J, Haling JR, Aversa R, Polyakov V, Zang R, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Ramurthy S, Sellers WR, Stuart DD.

Cancer Res. 2018 Mar 15;78(6):1537-1548. doi: 10.1158/0008-5472.CAN-17-2033. Epub 2018 Jan 17.

4.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.

5.

Design and Discovery of N-(2-Methyl-5'-morpholino-6'-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3'-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers.

Nishiguchi GA, Rico A, Tanner H, Aversa RJ, Taft BR, Subramanian S, Setti L, Burger MT, Wan L, Tamez V, Smith A, Lou Y, Barsanti PA, Appleton BA, Mamo M, Tandeske L, Dix I, Tellew JE, Huang S, Mathews Griner LA, Cooke VG, Van Abbema A, Merritt H, Ma S, Gampa K, Feng F, Yuan J, Wang Y, Haling JR, Vaziri S, Hekmat-Nejad M, Jansen JM, Polyakov V, Zang R, Sethuraman V, Amiri P, Singh M, Lees E, Shao W, Stuart DD, Dillon MP, Ramurthy S.

J Med Chem. 2017 Jun 22;60(12):4869-4881. doi: 10.1021/acs.jmedchem.6b01862. Epub 2017 Jun 8.

PMID:
28557458
6.

Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design.

Han W, Ding Y, Xu Y, Pfister K, Zhu S, Warne B, Doyle M, Aikawa M, Amiri P, Appleton B, Stuart DD, Fanidi A, Shafer CM.

J Med Chem. 2016 Apr 14;59(7):3034-45. doi: 10.1021/acs.jmedchem.5b01657. Epub 2016 Mar 29.

PMID:
27002243
7.

Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.

Holderfield M, Nagel TE, Stuart DD.

Br J Cancer. 2014 Aug 12;111(4):640-5. doi: 10.1038/bjc.2014.139. Epub 2014 Mar 18. Review.

8.

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors.

Das Thakur M, Stuart DD.

Clin Cancer Res. 2014 Mar 1;20(5):1074-80. doi: 10.1158/1078-0432.CCR-13-0103. Epub 2013 Dec 18. Review.

9.

The evolution of melanoma resistance reveals therapeutic opportunities.

Das Thakur M, Stuart DD.

Cancer Res. 2013 Oct 15;73(20):6106-10. doi: 10.1158/0008-5472.CAN-13-1633. Epub 2013 Oct 4. Review.

10.

Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.

Liu X, Ide JL, Norton I, Marchionni MA, Ebling MC, Wang LY, Davis E, Sauvageot CM, Kesari S, Kellersberger KA, Easterling ML, Santagata S, Stuart DD, Alberta J, Agar JN, Stiles CD, Agar NY.

Sci Rep. 2013 Oct 4;3:2859. doi: 10.1038/srep02859.

11.

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.

Holderfield M, Merritt H, Chan J, Wallroth M, Tandeske L, Zhai H, Tellew J, Hardy S, Hekmat-Nejad M, Stuart DD, McCormick F, Nagel TE.

Cancer Cell. 2013 May 13;23(5):594-602. doi: 10.1016/j.ccr.2013.03.033.

12.

Targeting RAF-MEK-ERK kinase-scaffold interactions in cancer.

Stuart DD, Sellers WR.

Nat Med. 2013 May;19(5):538-40. doi: 10.1038/nm.3195. No abstract available.

PMID:
23652103
13.

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.

Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, Dummer R, McMahon M, Stuart DD.

Nature. 2013 Feb 14;494(7436):251-5. doi: 10.1038/nature11814. Epub 2013 Jan 9.

14.

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A.

Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475.

15.

Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies.

Ettenberg SA, Charlat O, Daley MP, Liu S, Vincent KJ, Stuart DD, Schuller AG, Yuan J, Ospina B, Green J, Yu Q, Walsh R, Li S, Schmitz R, Heine H, Bilic S, Ostrom L, Mosher R, Hartlepp KF, Zhu Z, Fawell S, Yao YM, Stover D, Finan PM, Porter JA, Sellers WR, Klagge IM, Cong F.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15473-8. doi: 10.1073/pnas.1007428107. Epub 2010 Aug 16.

16.

High efficiency entrapment of antisense oligonucleotides in liposomes.

Stuart DD, Semple SC, Allen TM.

Methods Enzymol. 2004;387:171-88. No abstract available.

PMID:
15172164
17.
18.
19.

Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects.

Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen TM, Calabretta B, Ponzoni M.

J Natl Cancer Inst. 2000 Feb 2;92(3):253-61.

PMID:
10655443
20.
21.

Optical effects of UV-A and UV-B radiation on the cultured bovine lens.

Stuart DD, Cullen AP, Sivak JG, Doughty MJ.

Curr Eye Res. 1994 May;13(5):371-6.

PMID:
8055700
22.

Optical performance of the bovine lens before and after cold cataract.

Sivak JG, Stuart DD, Weerheim JA.

Appl Opt. 1992 Jul 1;31(19):3616-20. doi: 10.1364/AO.31.003616.

PMID:
20725332
23.

Methionine intake in rainbow trout (Oncorhynchus mykiss), relationship to cataract formation and the metabolism of methionine.

Cowey CB, Cho CY, Sivak JG, Weerheim JA, Stuart DD.

J Nutr. 1992 May;122(5):1154-63.

PMID:
1564569
24.

UV-B radiation and the optical properties of cultured bovine lenses.

Stuart DD, Sivak JG, Cullen AP, Weerheim JA, Monteith CA.

Curr Eye Res. 1991 Feb;10(2):177-84. Erratum in: Curr Eye Res 1991 Mar;10(3):275.

PMID:
2036809
25.

An improved radiolabeling technique of ivalon and its use for dynamic monitoring of complications during therapeutic transcatheter embolization.

Sirr SA, Johnson TK, Stuart DD, Stanchfield WR, Cardella JF, duCret RP, Boudreau RJ.

J Nucl Med. 1989 Aug;30(8):1399-404.

26.

Thyroxine replacement requirements in hypothyroid patients receiving phenytoin.

Blackshear JL, Schultz AL, Napier JS, Stuart DD.

Ann Intern Med. 1983 Sep;99(3):341-2. No abstract available.

PMID:
6614682
27.

Thyroid function tests simulating Graves' disease in alcoholic hepatitis.

Stuart DD, Schultz AL.

Ann Intern Med. 1978 Oct;89(4):514-5. No abstract available.

PMID:
581257
28.

Diabetic gustatory sweating.

Stuart DD.

Ann Intern Med. 1978 Aug;89(2):223-4. No abstract available.

PMID:
677588

Supplemental Content

Loading ...
Support Center